Effects of omega-3 polyunsaturated fatty acid supplementation in patients with chronic chagasic cardiomyopathy: study protocol for a randomized controlled trial

Paula S Silva, Gilberto Marcelo Sperandio da Silva, Andréa P de Souza, Claudia S A Cardoso, Cristiane A Fonseca, Patricia D Brito, Roberto M Saraiva, Pedro E A Brasil, Roberta O Pinheiro, Alejandro M Hasslocher-Moreno, Sérgio S Xavier, Andréa S Sousa, Paula S Silva, Gilberto Marcelo Sperandio da Silva, Andréa P de Souza, Claudia S A Cardoso, Cristiane A Fonseca, Patricia D Brito, Roberto M Saraiva, Pedro E A Brasil, Roberta O Pinheiro, Alejandro M Hasslocher-Moreno, Sérgio S Xavier, Andréa S Sousa

Abstract

Background: Chronic chagasic cardiomyopathy is an inflammatory disease that occurs in approximately 30% of patients infected by the protozoan Trypanosoma cruzi, and it has a profile of high morbidity and mortality. The worst prognosis and the progression of this cardiomyopathy are associated with an exacerbated immune response and the production of proinflammatory cytokines, which also occur in other cardiomyopathies. Some nutrients, including omega-3 polyunsaturated fatty acids (PUFAs), promote the inhibition and/or stimulation of cytokine production. The objective of this trial is to study the effects of omega-3 PUFA supplementation on the inflammatory response and lipid profile in patients with chronic chagasic cardiomyopathy.

Methods/design: This is a parallel, randomized, placebo-controlled, double-blind clinical trial with 40 patients that will be conducted at a reference unit for Chagas disease patients, where the patients will be selected. The study will include patients with chronic chagasic cardiomyopathy who are 18 years of age or older. The exclusion criteria are (a) ongoing diarrheal disease, (b) inflammatory bowel disease, (c) diabetes or other endocrine disease, (d) use of fibrates, niacin, or statins, (e) use of anti-inflammatory drugs, (f) pregnant and lactating women, (g) use of vitamin, mineral, or omega-3 supplementation during the previous 30 days, (h) hospital admission during the study, and (i) other associated cardiomyopathies. The intervention will be treatment with omega-3 PUFAs at a dose of 3 g/day for 8 weeks, compared to placebo (corn oil). The primary endpoints will be the concentrations of inflammatory markers (interleukin (IL)-1, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)α, interferon (IFN)γ, and transforming growth factor (TGF)β). Secondary endpoints will be the fasting glucose, lipid, and anthropometric profiles. For statistical analysis, we plan to run either a t test or Wilcoxon test (numerical variables) and Pearson's χ2 or Fisher's exact test (categorical data), as appropriate.

Discussion: Evidence suggests that the anti-inflammatory action of omega-3 PUFAs may have beneficial effects on chronic chagasic cardiomyopathy, as shown for other cardiomyopathies, due to improved control of the inflammatory response. At the end of the study, we predict that patients will have lower inflammatory markers and an improved metabolic and anthropometric profile.

Trial registration: Current Controlled Trials NCT01863576.

Figures

Figure 1
Figure 1
Study flow diagram for omega-3 supplementation in patients with chronic chagasic cardiomyopathy.

References

    1. Rassi A, Rassi A, Marcondes de Rezende J. American trypanosomiasis (Chagas disease) Infect Dis Clin North Am. 2012;26:275–291. doi: 10.1016/j.idc.2012.03.002.
    1. Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:1388–1402. doi: 10.1016/S0140-6736(10)60061-X.
    1. Ministério da Saúde. Secretaria de Vigilância em Saúde. Brazilian consensus on Chagas disease [in Portuguese] Rev Soc Bras Med Trop. 2005;38(Suppl 3):7–29.
    1. Dias JC. The indeterminate form of human chronic Chagas’ disease: a clinical epidemiological review. Rev Soc Bras Med Trop. 1989;22:147–156. doi: 10.1590/S0037-86821989000300007.
    1. Biolo A, Ribeiro AL, Clausell N. Chagas cardiomyopathy - where do we stand after a hundred years? Prog Cardiovasc Dis. 2010;52:300–316. doi: 10.1016/j.pcad.2009.11.008.
    1. Mady C, Nacruth R. Natural history of chronic Chagas’ heart disease: prognosis factors. Sao Paulo Med J. 1995;113:791–796. doi: 10.1590/S1516-31801995000200009.
    1. Marin Neto JA, Simões MV, Sarabanda AV. Chagas’ heart disease. Arq Bras Cardiol. 1999;72:247–280.
    1. Rassi A Jr, Rassi A, Little WC. Chagas’ heart disease. Clin Cardiol. 2000;23:883–889. doi: 10.1002/clc.4960231205.
    1. Ribeiro AL, Nunes MP, Teixeira MM, Rocha MOC. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol. 2012;9:576–589. doi: 10.1038/nrcardio.2012.109.
    1. Castro C, Prata A, Macêdo V. A folow-up period of 13 years prospective study in 190 chagasic patients of Mambaí, Goiás, State, Brazil. Rev Soc Bras Med Trop. 2001;34:309–318.
    1. Rocha MOC, Ribeiro ALP, Teixeira MM. Clinical management of chronic Chagas cardiomyopathy. Front Biosci. 2003;8:e44–e54. doi: 10.2741/926.
    1. Punukollu G, Gowda RM, Khan IA, Navarro VS, Vasavada BC. Clinical aspects of the Chagas’ heart disease. Int J Cardiol. 2007;115:279–283. doi: 10.1016/j.ijcard.2006.03.004.
    1. Sher A, Gazzinelli RT, Oswald IP, Clerici M, Kullberg M, Pearce EJ, Berzofsky JA, Mosmann TR, James SL, Morse HC 3rd. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev. 1992;127:183–204. doi: 10.1111/j.1600-065X.1992.tb01414.x.
    1. Bahia-Oliveira LM, Gomes JA, Rocha MO, Moreira MC, Lemos EM, Luz ZM, Pereira ME, Coffman RL, Dias JC, Cançado JR, Gazzinelli G, Corrêa-Oliveira R. IFN-gamma in human Chagas’ disease: protection or pathology? Braz J Med Biol Res. 1998;31:127–131.
    1. Gomes JAS, Bahia-Oliveira LMG, Rocha MOC, Martins-Filho OA, Gazzinelli G, Correa-Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas’ disease is due to a Th1-specific immune response. Infect Immun. 2003;71:1185–1193. doi: 10.1128/IAI.71.3.1185-1193.2003.
    1. Araújo-Jorge TC, Waghabi MC, de NC SM, Keramidas M, Bailly S, Feige J-J. Pivotal role for TGF-beta in infectious heart disease: the case of Trypanosoma cruzi infection and consequent chagasic myocardiopathy. Cytokine Growth Factor Rev. 2008;19:405–413. doi: 10.1016/j.cytogfr.2008.08.002.
    1. Pérez-Fuentes R, Guégan J-F, Barnabé C, López-Colombo A, Salgado-Rosas H, Torres-Rasgado E, Briones B, Romero-Díaz M, Ramos-Jiménez J, Sánchez-Guillén M del C. Severity of chronic Chagas disease is associated with cytokine/antioxidant imbalance in chronically infected individuals. Int J Parasitol. 2003;33:293–299. doi: 10.1016/S0020-7519(02)00283-7.
    1. Dutra WO, Rocha MOC, Teixeira MM. The clinical immunology of human Chagas disease. Trends Parasitol. 2005;21:581–587. doi: 10.1016/j.pt.2005.09.007.
    1. Cunha-Neto E, Nogueira LG, Teixeira PC, Ramasawmy R, Drigo SA, Goldberg AC, Fonseca SG, Bilate AM, Kalil J. Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy. Mem Inst Oswaldo Cruz. 2009;104(Suppl 1):252–258.
    1. Perini JÂDL, Stevanato FB, Sargi SC, Visentainer JEL, Dalalio MMDO, Matshushita M, Souza NED, Visentainer JV. Omega-3 and omega-6 polyunsaturated fatty acids: metabolism in mammals and immune response. Rev Nutr. 2010;23:1075–1086. doi: 10.1590/S1415-52732010000600013.
    1. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999;70:560S–569S.
    1. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2013;75:645–662.
    1. Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol. 2006;48:677–685. doi: 10.1016/j.jacc.2006.03.052.
    1. de Truchis P, Kirstetter M, Perier A, Meunier C, Zucman D, Force G, Doll J, Katlama C, Rozenbaum W, Masson H, Gardette J, Melchior J-C. Reduction in triglyceride level with n-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr. 2007;44:278–285. doi: 10.1097/QAI.0b013e31802c2f3d.
    1. Thusgaard M, Christensen JH, Mørn B, Andersen TS, Vige R, Arildsen H, Schmidt EB, Nielsen H. Effect of fish oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoproteins and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: a randomized, double-blind, placebo-controlled study. Scand J Infect Dis. 2009;41:760–766. doi: 10.1080/00365540903168056.
    1. Anderson M, Fritsche KL. (n-3) Fatty acids and infectious disease resistance. J Nutr. 2002;132:3566–3576.
    1. Trebble TM, Wootton SA, Miles EA, Mullee M, Arden NK, Ballinger AB, Stroud MA, Burdge GC, Calder PC. Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation. Am J Clin Nutr. 2003;78:376–382.
    1. Damsgaard CT, Frøkiaer H, Lauritzen L. The effects of fish oil and high or low linoleic acid intake on fatty acid composition of human peripheral blood mononuclear cells. Br J Nutr. 2008;99:147–154.
    1. Damsgaard CT, Lauritzen L, Calder PC, Kjaer TR, Frøkiaer H. Reduced ex vivo interleukin-6 production by dietary fish oil is not modified by linoleic acid intake in healthy men. J Nutr. 2009;139:1410–1414. doi: 10.3945/jn.108.102269.
    1. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346:1113–1118. doi: 10.1056/NEJMoa012918.
    1. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study. Am J Clin Nutr. 2003;77:319–325.
    1. Frenoux JM, Prost ED, Belleville JL, Prost JL. A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats. J Nutr. 2001;131:39–45.
    1. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–1230. doi: 10.1016/S0140-6736(08)61239-8.
    1. Sposito AC, Caramelli B, Fonseca FAH, Bertolami MC, Afiune Neto A, Souza AD, Lottenberg AMP, Chacra AP, Faludi AA, Loures-Vale AA, Carvalho AC, Duncan B, Gelonese B, Polanczyk C, Rodrigues Sobrinho CRM, Scherr C, Karla C, Armaganijan D, Moriguchi E, Saraiva F, Pichetti G, Xavier HT, Chaves H, Borges JL, Diament J, Guimarães JI, Nicolau JC, Dos Santos JE, de Lima JJG, Vieira JL. IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology [in Portuguese] Arq Bras Cardiol. 2007;88(Suppl 1):2–19.
    1. Kim W, McMurray DN, Chapkin RS. n-3 polyunsaturated fatty acids-physiological relevance of dose. Prostaglandins Leukot Essent Fatty Acids. 2010;82:155–158. doi: 10.1016/j.plefa.2010.02.028.
    1. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J. 2011;161:e1–e9. doi: 10.1016/j.ahj.2010.10.021.
    1. Freeman MP, Sinha P. Tolerability of omega-3 fatty acid supplements in perinatal women. Prostaglandins Leukot Essent Fatty Acids. 2007;77:203–208. doi: 10.1016/j.plefa.2007.09.004.
    1. Faber J, Berkhout M, Fiedler U, Avlar M, Witteman BJ, Vos AP, Henke M, Garssen J, van Helvoort A, Otten MH, Arends J. Rapid EPA and DHA incorporation and reduced PGE(2) levels after one week intervention with a medical food in cancer patients receiving radiotherapy, a randomized trial. Clin Nutr. 2013;32:338–345. doi: 10.1016/j.clnu.2012.09.009.
    1. Vieira MJ, Gama-Rodrigues JJ, Habr-Gama A, Faintuch J, Waitzberg DL, Pinotti HW. Preoperative assessment in cases of adult megacolon suffering from moderate malnutrition. Nutrition. 1996;12:491–495. doi: 10.1016/S0899-9007(96)91724-4.
    1. Penhavel FAS, Waitzberg DL, Trevenzol HP, Alves L, Zilberstein B, Gama-Rodrigues J. Pre-and postoperative nutritional evaluation in patients with chagasic megaesophagus. Nutr Hosp. 2004;19:89–94.
    1. Celano RMG, Ebram Neto J, Bottoni A, Gagliardi D. Pre- operatory nutritional evaluation of patients with non-advanced megaesophagus. Rev Col Bras Cir. 2007;34:147–152. doi: 10.1590/S0100-69912007000300003.
    1. Geraix J, Ardisson LP, Marcondes-Machado J, Pereira PCM. Clinical and nutritional profile of individuals with Chagas disease. Braz J Infect Dis. 2007;11:411–414. doi: 10.1590/S1413-86702007000400008.
    1. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant. 2006;25:834–838. doi: 10.1016/j.healun.2006.03.005.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
    1. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr. 1981;34:2540–2545.
    1. Frisancho AR. Anthropometric Standards for the Assessment of Growth and Nutritional Status. Ann Arbor, MI: University of Michigan; 1990.
    1. Murphy PM, Blackshaw GRJC, Paris HJ, Edwards P, Barry JD, Lewis WG. Prospective evaluation of nutritional status related to body mass indices and outcomes after modified D2 gastrectomy for carcinoma. Clin Nutr. 2004;23:477–483. doi: 10.1016/j.clnu.2003.07.009.
    1. Thompson FE, Byers T. Dietary assessment resource manual. J Nutr. 1994;124:2245S–2317S.
    1. Hebert JR, Gupta PC, Bhonsle RB, Sinor PN, Mehta H, Mehta FS. Development and testing of a quantitative food frequency questionnaire for use in Gujarat, India. Public Health Nutr. 1999;2:39–50.
    1. Monteiro CA, Mondini L, Costa RB. Secular changes in dietary patterns in the metropolitan areas of Brazil (1988–1996) Rev Saude Publica. 2000;34:251–258. doi: 10.1590/S0034-89102000000300007.
    1. Harris WS, Mozaffarian D, Lefevre M, Toner CD, Colombo J, Cunnane SC, Holden JM, Klurfeld DM, Morris MC, Whelan J. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr. 2009;139:804S–819S. doi: 10.3945/jn.108.101329.
    1. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
    1. Lauritsen JM, Bruus M. EpiData (version 3). A Comprehensive Tool for Validated Entry and Documentation of Data. Odense, Denmark: The EpiData Association; 2003.
    1. SPSS Inc. SPSS for Windows, Version 16.0. [ ]
    1. Salvador MB, Sarkis KS, Silva RG, Zerbini CA de F, Martini LA. Avaliação da ingestão de ácidos graxos, antioxidantes e da composição corporal em mulheres com artrite reumatóide [Fatty acids, antioxidants and body composition evaluation in woman with reumathoid arthritis] Nutrire Rev Soc Bras Aliment Nutr. 2008;33:17–30.
    1. Kew S, Mesa MD, Tricon S, Buckley R, Minihane AM, Yaqoob P. Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans. Am J Clin Nutr. 2004;79:674–681.
    1. Chongsuvivatwong V. Epicalc: epidemiological calculator. [ ]
    1. Government of Brazil. The National Committee for Ethics in Research-MOH (CONEP/MS) [ ]
    1. Santos RD, Gagliardi ACM, Xavier HT, Magnoni CD, Cassani R, Lottenberg AM, Casella A, Araujo DB, Cesena FY, Alves RJ, Faludi AA, Geloneze B, Scherr C, Kovacs C, Tomazzela C, Carla C, Barrera-Arellano D, Cintra D, Quintão E, Nakandakare ER, Fonseca FAH, Pimentel I, Santos JE, Bertolami MC, Rogero M, Izar MCO, Nakasato M, Damasceno NRT, Maranhão R, Cassani RSL, Perim R, Ramos S. I Diretriz sobre o consumo de gorduras e saúde cardiovascular [in Portuguese] Arq Bras Cardiol. 2013;100:1–40.
    1. Rafraf M, Mohammadi E, Asghari-Jafarabadi M, Farzadi L. Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome. J Am Coll Nutr. 2012;31:361–368. doi: 10.1080/07315724.2012.10720443.
    1. Xin W, Wei W, Li X. Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2012;12:77. doi: 10.1186/1471-2261-12-77.
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. ACCF/AHA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–e327.
    1. Rocha Rodrigues DB, dos Reis MA, Romano A, Pereira SA de L, de PA TV, Tostes PA Jr, Rodrigues V Jr. In situ expression of regulatory cytokines by heart inflammatory cells in Chagas’ disease patients with heart failure. Clin Dev Immunol. 2012;2012:361730.
    1. Guedes PMM, Gutierrez FRS, Silva GK, Dellalibera-Joviliano R, Rodrigues GJ, Bendhack LM, Rassi A Jr, Rassi A, Schmidt A, Maciel BC, Marin Neto JA, Silva JS. Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas’ disease. PLoS Negl Trop Dis. 2012;6:e1630. doi: 10.1371/journal.pntd.0001630.
    1. Corrêa-Oliveira R, Gomes J, Lemos EM, Cardoso GM, Reis DD, Adad S, Crema E, Martins-Filho OA, Costa MO, Gazzinelli G, Bahia-Oliveira LM. The role of the immune response on the development of severe clinical forms of human Chagas disease. Mem Inst Oswaldo Cruz. 1999;94(Suppl 1):253–255.
    1. Penas F, Mirkin GA, Hovsepian E, Cevey A, Caccuri R, Sales ME, Goren NB. PPARγ ligand treatment inhibits cardiac inflammatory mediators induced by infection with different lethality strains of Trypanosoma cruzi. Biochim Biophys Acta. 2013;1832:239–248. doi: 10.1016/j.bbadis.2012.08.007.
    1. Song C, Li X, Leonard BE, Horrobin DF. Effects of dietary n-3 or n-6 fatty acids on interleukin-1β-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res. 2003;44:1984–1991. doi: 10.1194/jlr.M300217-JLR200.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する